Shares of Array BioPharma Inc. (ARRY) jumped more than 81% on Monday, following positive top-line results from Part 1 of the phase III study evaluating the combination of LGX818 and MEK162 compared to Vemurafenib alone in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.
from RTT - Biotech http://ift.tt/2cREXLh
via IFTTT
No comments:
Post a Comment